Chitkara College of Pharmacy, Chitkara University, Punjab, India.
Department of Ocular Pharmacology, All India Institute of Medical Sciences, New Delhi, India.
Endocr Metab Immune Disord Drug Targets. 2021;21(6):1053-1065. doi: 10.2174/1871530320666201029142113.
Diabetic retinopathy is amongst the most common microvascular complications associated with diabetes. Controlling blood glucose level alone cannot manage diabetes associated complications. Thus, mechanisms that additionally prevent diabetes associated complications are the need of the hour, driving the researchers towards herbal therapies. Terminalia catappa is renowned for its anti-inflammatory, antioxidant, anti-hyperglycemic and anti-angiogenic activity. The current study explores the effect of Terminalia catappa fruit extract on streptozotocin-induced diabetic retinopathy in rats.
Streptozotocin-induced chronic diabetic rat model was utilized in the study. The hydroalcoholic fruit extract of T. catappa in 20mg/kg, 30mg/kg and 40mg/kg dose and standard anti-diabetic drug, glibenclamide (10mg/kg) was given orally. Retinopathy was evaluated by monitoring lenticular, fundus images and measuring arteriole and venule tortuosity index. Oxidative, angiogenic and inflammatory biomarkers were assessed at the 12th week in the retinal homogenate. Histopathological changes in the retina were also examined. Data was analyzed using one-way Repeated Measure ANOVA followed by the Mann-Whitney test.
The hydro-alcoholic fruit extract of T. catappa significantly decreased blood glucose (p<0.001) in a dose-dependent manner in diabetic rats. Cataract lens was observed in all experimental groups and became clear (grade 0) with 40mg/kg and with 40mg/kg along with glibenclamide at the eighth and sixth week, respectively. The hydro-alcoholic fruit extract in all three doses significantly reduced (p<0.01) arteriole and venule tortuosity in diabetic rats. T. catappa in all three doses in diabetic rats showed a modulatory effect in oxidative, angiogenic and inflammatory biomarkers.
T. catappa reverses diabetes-induced retinopathy by anti-hyperglycemic, anti-oxidant, anti-angiogenic and anti-inflammatory actions, and thus has a potential to be used in diabetes-induced retinopathy.
糖尿病视网膜病变是糖尿病最常见的微血管并发症之一。单独控制血糖水平并不能控制糖尿病相关并发症。因此,需要寻找额外的机制来预防糖尿病相关并发症,这促使研究人员转向草药疗法。诃子以其抗炎、抗氧化、降血糖和抗血管生成活性而闻名。本研究探讨了诃子果提取物对链脲佐菌素诱导的糖尿病大鼠视网膜病变的影响。
本研究采用链脲佐菌素诱导的慢性糖尿病大鼠模型。以 20mg/kg、30mg/kg 和 40mg/kg 剂量以及标准抗糖尿病药物格列本脲(10mg/kg)口服给予诃子水醇提物。通过监测晶状体、眼底图像以及测量小动脉和小静脉扭曲指数来评估视网膜病变。在第 12 周评估视网膜中的氧化、血管生成和炎症生物标志物。还检查了视网膜的组织病理学变化。数据采用单向重复测量方差分析,然后进行曼-惠特尼检验。
诃子水醇提物以剂量依赖性方式显著降低糖尿病大鼠的血糖(p<0.001)。所有实验组均观察到白内障晶状体,40mg/kg 剂量组和 40mg/kg 联合格列本脲组在第八和第六周分别变为清晰(等级 0)。三种剂量的诃子水醇提物均显著降低糖尿病大鼠的小动脉和小静脉扭曲(p<0.01)。三种剂量的诃子水醇提物在糖尿病大鼠中均显示出对氧化、血管生成和炎症生物标志物的调节作用。
诃子通过降血糖、抗氧化、抗血管生成和抗炎作用逆转糖尿病引起的视网膜病变,因此具有用于糖尿病性视网膜病变的潜力。